Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEXT: Adjuvant Nivolumab Following Chemo-Radiation in Localized Bladder Cancer
NCT03171025Phase 2Active, not recruiting
- Sponsor
- University of Utah
- Start
- Jul 2017
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in bladder cancer, sponsored by University of Utah. Primary endpoint: Failure-Free Survival at 2 years. Started Jul 2017; status: active, not recruiting.
02
Drugs
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT03171025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03171025.